U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H25NO3
Molecular Weight 267.3639
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METOPROLOL

SMILES

COCCC1=CC=C(OCC(O)CNC(C)C)C=C1

InChI

InChIKey=IUBSYMUCCVWXPE-UHFFFAOYSA-N
InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C15H25NO3
Molecular Weight 267.3639
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Mrtoprolol is a beta-adrenergic receptor blocking agent. In vitro and in vivo animal studies have shown that it has a preferential effect on beta-1 adrenoreceptors, chiefly located in cardiac muscle. Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Mrtoprolol is indicated for the treatment of hypertension, angina pectoris and myocardial infarction

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LOPRESSOR

Approved Use

Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ).

Launch Date

1978
Primary
LOPRESSOR

Approved Use

Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ).

Launch Date

1978
Primary
LOPRESSOR

Approved Use

Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ).

Launch Date

1978
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
76 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
279 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.8 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9 h
unknown
METOPROLOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
90%
unknown
METOPROLOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5000 mg single, oral
Overdose
Dose: 5000 mg
Route: oral
Route: single
Dose: 5000 mg
Sources:
unknown, 39 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 39 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Bradycardia...
AEs leading to
discontinuation/dose reduction:
Bradycardia (1 patient)
Sources:
7500 mg single, oral
Overdose
Dose: 7500 mg
Route: oral
Route: single
Dose: 7500 mg
Sources:
unknown, adult
n = 1
Health Status: unknown
Age Group: adult
Sex: unknown
Population Size: 1
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Bradycardia 1 patient
Disc. AE
5000 mg single, oral
Overdose
Dose: 5000 mg
Route: oral
Route: single
Dose: 5000 mg
Sources:
unknown, 39 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 39 years
Sex: F
Population Size: 1
Sources:
Death grade 5, 1 patient
Disc. AE
7500 mg single, oral
Overdose
Dose: 7500 mg
Route: oral
Route: single
Dose: 7500 mg
Sources:
unknown, adult
n = 1
Health Status: unknown
Age Group: adult
Sex: unknown
Population Size: 1
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
yes [Ki 570 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: coadministration of quinidine 100 mg and immediate release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life; Coadministration of metoprolol with gefitinib resulted in a 35% increase in the metoprolol area under plasma concentration-time curve from time zero to the time of the last quantifiable concentration; paroxetine increased the AUC of metoprolol three to five times, and significantly decreased systolic blood pressure and heart rate of patients;
Page: 3.0
minor
minor
minor
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.
1994 Oct
Early alterations of polyamine metabolism induced after acute administration of clenbuterol in mouse heart.
1999
Stopping the pills.
1999 Aug 14
Angioedema due to losartan.
1999 Sep
MERIT-HF mortality and morbidity data.
2000
Side effects of beta-blocker treatment for hypertension.
2000 Jun
Safety, hemodynamic profile, and feasibility of dobutamine stress technetium myocardial perfusion single-photon emission CT imaging for evaluation of coronary artery disease in the elderly.
2000 Mar
Syncope in pharmacologically unmasked Brugada syndrome: indication for an implantable defibrillator or an unresolved dilemma?
2001 Apr
Enantiomer separation by strong anion-exchange capillary electrochromatography with dynamically modified sulfated beta-cyclodextrin.
2001 Feb
Origins of heart rate variability: autonomic blockade of large magnitude, transient bradycardia in conscious rabbits.
2001 Feb
Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy.
2001 Feb
Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells.
2001 Feb 1
Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in rat cardiac myocytes.
2001 Feb 1
Hyperthyroid dementia: clinicoradiological findings and response to treatment.
2001 Feb 15
Selective beta(1)-blockade improves cardiac bioenergetics and function and decreases neuroendocrine activation in rats during early postinfarct remodeling.
2001 Feb 23
Acute renal ischemia model in dogs: effects of metoprolol.
2001 Jan
Evidence for the binding of beta-adrenoceptor blockers to microsomal Na+/K+-ATPase in guinea pig heart preparations.
2001 Jan
Silent ischemic interval on exercise test is a predictor of response to drug therapy: a randomized crossover trial of metoprolol versus diltiazem in stable angina.
2001 Jan
[Rhabdomyolysis as a rare complication of theophylline poisoning].
2001 Jan 15
The juxtaglomerular apparatus in young type-1 diabetic patients with microalbuminuria. Effect of antihypertensive treatment.
2001 Jun
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.
2001 Jun
Differing beta-blocking effects of carvedilol and metoprolol.
2001 Jun
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.
2001 Jun
Beta-blockade in chronic heart failure.
2001 Jun 12
Nebivolol, carvedilol and metoprolol do not influence cardiac Ca(2+) sensitivity.
2001 Jun 22
Behavioral-independent features of complex heartbeat dynamics.
2001 Jun 25
Effect of beta blockers on mortality and morbidity in persons treated for congestive heart failure.
2001 Mar
A preliminary study of beta-cyclodextrin/metoprolol tartrate inclusion complex for potential enantiomeric separation.
2001 Mar
Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade.
2001 Mar
How to manage atrial fibrillation: an update on recent clinical trials.
2001 Mar-Apr
An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
2001 May
Overview of the results of recent beta blocker trials.
2001 May
Carvedilol in the treatment of chronic heart failure.
2001 May
Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes.
2001 Sep 14
Patents

Sample Use Guides

Hypertension The dosage of Lopressor should be individualized. Lopressor should be taken with or immediately following meals. The usual initial dosage is 100 mg daily in single or divided doses, whether used alone or added to a diuretic. The dosage may be increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after 1 week of therapy. The effective dosage range is 100-450 mg per day. Dosages above 450 mg per day have not been studied. While once-daily dosing is effective and can maintain a reduction in blood pressure throughout the day, lower doses (especially 100 mg) may not maintain a full effect at the end of the 24-hour period, and larger or more frequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the day. Beta1 selectivity diminishes as the dose of Lopressor is increased. Angina Pectoris The dosage of Lopressor should be individualized. Lopressor should be taken with or immediately following meals. The usual initial dosage is 100 mg daily, given in two divided doses. The dosage may be gradually increased at weekly intervals until optimum clinical response has been obtained or there is pronounced slowing of the heart rate. The effective dosage range is 100-400 mg per day. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, the dosage should be reduced gradually over a period of 1-2 weeks (see WARNINGS). Myocardial Infarction Early Treatment: During the early phase of definite or suspected acute myocardial infarction, treatment with Lopressor can be initiated as soon as possible after the patient’s arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patient’s hemodynamic condition has stabilized. Treatment in this early phase should begin with the intravenous administration of three bolus injections of 5 mg of Lopressor each; the injections should be given at approximately 2-minute intervals. During the intravenous administration of Lopressor, blood pressure, heart rate, and electrocardiogram should be carefully monitored. In patients who tolerate the full intravenous dose (15 mg), Lopressor tablets, 50 mg every 6 hours, should be initiated 15 minutes after the last intravenous dose and continued for 48 hours. Thereafter, patients should receive a maintenance dosage of 100 mg twice daily (see Late Treatment below). Patients who appear not to tolerate the full intravenous dose should be started on Lopressor tablets either 25 mg or 50 mg every 6 hours (depending on the degree of intolerance) 15 minutes after the last intravenous dose or as soon as their clinical condition allows. In patients with severe intolerance, treatment with Lopressor should be discontinued (see WARNINGS). Late Treatment: Patients with contraindications to treatment during the early phase of suspected or definite myocardial infarction, patients who appear not to tolerate the full early treatment, and patients in whom the physician wishes to delay therapy for any other reason should be started on Lopressor tablets, 100 mg twice daily, as soon as their clinical condition allows. Therapy should be continued for at least 3 months. Although the efficacy of Lopressor beyond 3 months has not been conclusively established, data from studies with other beta blockers suggest that treatment should be continued for 1-3 years. Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Route of Administration: Other
0.01 to 0.1 uM metoprolol increased osteoblast proliferation, alkaline phosphatase activity, and calcium mineralization, and promoted the expression of osteogenic genes.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:30:20 GMT 2023
Edited
by admin
on Sat Dec 16 16:30:20 GMT 2023
Record UNII
GEB06NHM23
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METOPROLOL
HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
metoprolol [INN]
Common Name English
(RS)-METOPROLOL
Common Name English
METOPROLOL [HSDB]
Common Name English
METOPROLOL SLOW RELEASE
Common Name English
BEATROLOL
Brand Name English
CGP-2175
Code English
METOPROLOL [VANDF]
Common Name English
2-PROPANOL, 1-(4-(2-METHOXYETHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-
Systematic Name English
SEROKEN
Brand Name English
METOPROLOL [MART.]
Common Name English
1-(4-(2-METHOXYETHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-2-PROPANOL
Systematic Name English
1-(ISOPROPYLAMINO)-3-(4-(2-METHOXYETHYL)PHENOXY)PROPAN-2-OL
Systematic Name English
DL-METOPROLOL
Common Name English
METOPROLOL [USAN]
Common Name English
H-93/26
Code English
METOPROLOL, (±)-
Common Name English
Metoprolol [WHO-DD]
Common Name English
METOPROLOL [MI]
Common Name English
(±)-METOPROLOL
Common Name English
Classification Tree Code System Code
WHO-ATC C07FX03
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-ATC C07BB52
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
LIVERTOX NBK547984
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-ATC C07BB02
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
FDA ORPHAN DRUG 804220
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-ATC C07AB02
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-VATC QC07BB02
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-ATC C07FB02
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-ATC C07CB02
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-VATC QC07AB02
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-ATC C07FX05
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-VATC QC07AB52
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
NDF-RT N0000175556
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-VATC QC07CB02
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-VATC QC07FB02
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
NDF-RT N0000000161
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-ATC C07AB52
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
NCI_THESAURUS C29576
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
FDA ORPHAN DRUG 804320
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-VATC QC07BB52
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
WHO-ATC C07FB13
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
Code System Code Type Description
ECHA (EC/EINECS)
253-483-7
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
ALTERNATIVE
CAS
51384-51-1
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
WIKIPEDIA
METOPROLOL
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
DAILYMED
GEB06NHM23
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
ECHA (EC/EINECS)
257-166-4
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID2023309
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
CAS
37350-58-6
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
SUPERSEDED
SMS_ID
100000076066
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
MESH
D008790
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
LACTMED
Metoprolol
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
ChEMBL
CHEMBL13
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
FDA UNII
GEB06NHM23
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
RXCUI
6918
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY RxNorm
DRUG BANK
DB00264
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
CHEBI
6904
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
HSDB
6531
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
IUPHAR
553
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
EVMPD
SUB14568MIG
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
MERCK INDEX
m7498
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY Merck Index
DRUG CENTRAL
1786
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
NCI_THESAURUS
C61845
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
INN
3471
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
CAS
54163-88-1
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
SUPERSEDED
PUBCHEM
4171
Created by admin on Sat Dec 16 16:30:23 GMT 2023 , Edited by admin on Sat Dec 16 16:30:23 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
SHORT-ACTING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
O-demethylmetoprolol is a pharmacologically active urinary metoprolol metabolite that has 5 to 10X less potent than metoprolol.
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE ACTIVE -> PARENT
Alpha-hydroxymetoprololhas 5 to 10X less potent than metoprolol.
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC